81 related articles for article (PubMed ID: 9714327)
1. Effect of fantofarone, a new Ca2+ channel antagonist, on angioplasty-induced vasospasm in an atherosclerotic rabbit model.
Dongay B; Dol-Gleizes F; Herbert JM
Biochem Pharmacol; 1998 Jun; 55(12):2047-50. PubMed ID: 9714327
[TBL] [Abstract][Full Text] [Related]
2. Effects of two chemically related new Ca2+ channel antagonists, SR33557 (fantofarone) and SR33805, on the L-type cardiac channel.
Romey G; Bois P; Lazdunski M
Eur J Pharmacol; 1994 Sep; 263(1-2):101-5. PubMed ID: 7821341
[TBL] [Abstract][Full Text] [Related]
3. In vitro characterization of a novel Ca2+ entry blocker: SR 33805.
Chatelain P; Clinet M; Polster P; Christophe B; Manning AS
Eur J Pharmacol; 1993 Aug; 246(3):181-93. PubMed ID: 8223943
[TBL] [Abstract][Full Text] [Related]
4. Fantofarone (SR 33557): cardiovascular actions in anesthetized dogs.
Barthélémy G; Chatelain P; Manning A
Arch Int Pharmacodyn Ther; 1994; 327(2):204-19. PubMed ID: 7979829
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers.
Bellissant E; Giudicelli JF
Br J Clin Pharmacol; 1999 Dec; 48(6):801-10. PubMed ID: 10594483
[TBL] [Abstract][Full Text] [Related]
6. Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels.
Romey G; Lazdunski M
J Pharmacol Exp Ther; 1994 Dec; 271(3):1348-52. PubMed ID: 7996445
[TBL] [Abstract][Full Text] [Related]
7. Effects of serotonin-receptor blockade on angioplasty-induced vasospasm in an atherosclerotic rabbit model.
Sigal SL; Gellman J; Sarembock IJ; LaVeau PJ; Chen QS; Cabin HS; Ezekowitz MD
Arterioscler Thromb; 1991; 11(3):770-83. PubMed ID: 1827592
[TBL] [Abstract][Full Text] [Related]
8. Fantofarone (SR33557): effects on myocardial oxygen consumption and coronary blood flow.
Hodeige D; Chatelain P; Manning A
Pharmacology; 1994 Jan; 48(1):49-55. PubMed ID: 8309987
[TBL] [Abstract][Full Text] [Related]
9. Synergy between two calcium channel blockers, verapamil and fantofarone (SR33557), in reversing chloroquine resistance in Plasmodium falciparum.
Adovelande J; Delèze J; Schrével J
Biochem Pharmacol; 1998 Feb; 55(4):433-40. PubMed ID: 9514077
[TBL] [Abstract][Full Text] [Related]
10. Vascular calcium overload produced by vitamin D3, in rats. Effect of treatment with SR 33805, a novel calcium entry blocker.
Chatelain P; Mouton J; Feys G; Laruel A; Manning AS
Cardiovasc Res; 1995 Dec; 30(6):1038-43. PubMed ID: 8746222
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of monotherapy with fantofarone, a novel calcium channel antagonist, in patients with chronic stable angina pectoris. Fantofarone Study Group.
Glasser SP; Singh SN; Humen DP
J Clin Pharmacol; 1997 Jan; 37(1):53-7. PubMed ID: 9048273
[TBL] [Abstract][Full Text] [Related]
12. Interaction of the calcium antagonist fantofarone with phospholipids: electrostatic effects.
Chatelain P; Matteazzi JR; Laruel R
Biochem Pharmacol; 1994 Oct; 48(7):1393-8. PubMed ID: 7945438
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of verapamil and nitroglycerin on contraction and cytosolic Ca2+ levels in cerebrovascular smooth muscle during chronic cerebral vasospasm.
Tanaka Y; Masuzawa T; Saito M; Yamada T
Neurol Med Chir (Tokyo); 2001 May; 41(5):238-44; discussion 244-5. PubMed ID: 11396303
[TBL] [Abstract][Full Text] [Related]
14. Cerebrovascular selectivity and vasospasmolytic action of the novel calcium antagonist (+/-)-(E)-1-(3-fluoro-6, 11-dihydrodibenz[b,e]oxepin-11-yl)-4-(3-phenyl-2-propenyl)-piperazine dimaleate in isolated cerebral arteries of the rabbit and dog.
Minato H; Hashizume M; Masuda Y; Fujitani B; Hosoki K
Arzneimittelforschung; 1997 Apr; 47(4):339-46. PubMed ID: 9150852
[TBL] [Abstract][Full Text] [Related]
15. SR 33557, a novel calcium entry blocker. I. In vitro isolated tissue studies.
Polster P; Christophe B; Van Damme M; Houlliche A; Chatelain P
J Pharmacol Exp Ther; 1990 Nov; 255(2):593-9. PubMed ID: 1700816
[TBL] [Abstract][Full Text] [Related]
16. New drug binding sites in Ca2+ channels.
Spedding M; Kenny B; Chatelain P
Trends Pharmacol Sci; 1995 Apr; 16(4):139-42. PubMed ID: 7610500
[TBL] [Abstract][Full Text] [Related]
17. Binding of fantofarone, a novel Ca2+ antagonist, to serum albumin: a fluorescence study.
Chatelain P; Matteazzi JR; Laruel R
J Pharm Sci; 1994 May; 83(5):674-6. PubMed ID: 8071819
[TBL] [Abstract][Full Text] [Related]
18. SR33557, an indolizinsulfone blocker of Ca2+ channels: identification of receptor sites and analysis of its mode of action.
Schmid A; Romey G; Barhanin J; Lazdunski M
Mol Pharmacol; 1989 Jun; 35(6):766-73. PubMed ID: 2543910
[TBL] [Abstract][Full Text] [Related]
19. Angioplasty-induced vasospasm in rabbit model. Mechanisms and treatment.
LeVeen RF; Wolf GL; Biery D
Invest Radiol; 1985 Dec; 20(9):938-44. PubMed ID: 2934349
[TBL] [Abstract][Full Text] [Related]
20. Novel heterocyclic analogues of the new potent class of calcium entry blockers: 1-[[4-(aminoalkoxy)phenyl]sulfonyl]indolizines.
Gubin J; de Vogelaer H; Inion H; Houben C; Lucchetti J; Mahaux J; Rosseels G; Peiren M; Clinet M; Polster P
J Med Chem; 1993 May; 36(10):1425-33. PubMed ID: 8496910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
